Advertisement

COVID-19 May Trigger Alzheimer's-Like Protein Buildup In Brain And Eyes, Study Finds

The study contributes to understanding the complex relationship between COVID-19 and neurological health.

COVID-19 May Trigger Alzheimer's-Like Protein Buildup In Brain And Eyes, Study Finds
Representative image.
  • COVID-19 can cause protein buildup in the brain and eyes, similar to Alzheimer's disease
  • Amyloid beta accumulation was found in retinal tissue of COVID-19 patients, indicating retinal damage
  • Neuropilin-1 protein may allow virus entry into eyes and brains, contributing to amyloid beta increase
Did our AI summary help?
Let us know.

New research suggests that COVID-19 can lead to protein build-up similar to that seen in Alzheimer's patients, not just in the brain but also in the eyes. Elevated amyloid beta levels were found in the retinal tissue of people who had COVID-19, similar to Alzheimer's-like retinal conditions. Notably, Amyloid beta buildup is associated with Alzheimer's disease.

Researchers analysed two proteins, neuropilin-1 (NRP1) and angiotensin-converting enzyme 2 (ACE2). The NRP1 protein may serve as an entry point for viruses into human eyes and brains. Researchers found that introducing an NRP1 inhibitor countered the amyloid beta increase caused by COVID-19's spike protein.

Also Read | Breakthrough In Male Birth Control As Hormone-Free Pill Passes Human Safety Test

The study, led by Yale University and published in Science Advances, sheds light on COVID-19 brain fog, which was a commonly reported symptom following infection. The researchers believe that amyloid beta may act as a bodyguard for the brain, indicating underlying danger.

"There is growing evidence linking COVID-19 and brain fog, a commonly reported symptom following infection," senior author Brian Hafler, ophthalmologist at Yale School of Medicine, said as quoted by Science Alert.

"While the mechanisms of brain fog after COVID-19 are not fully understood, scientists have found that SARS-CoV-2 can induce amyloid beta accumulation in the central nervous system."

The research team is conducting clinical studies to determine if COVID-19 increases the long-term risk of developing Alzheimer's disease, to explore NRP1 inhibitors as potential therapeutics.

Also Read | Experts Say Mental Health In Workplace Is Important, "Stress Is Not A Badge Of Honour"

The involvement of NRP1 in amyloid beta aggregation provides a specific molecular target for future investigation. Other viruses may trigger similar amyloid beta buildups, as there's a need for further research.

This study contributes to understanding the complex relationship between COVID-19 and neurological health. "Our study showed that exposure to SARS-CoV-2, in particular spike protein, can lead to the formation of amyloid beta aggregates in both human retinal tissue and retinal organoids," Hafler says.

Track Latest News Live on NDTV.com and get news updates from India and around the world

Follow us:
Listen to the latest songs, only on JioSaavn.com